Search results
Weight loss drugs like Wegovy have taken the country by storm. But who can afford them?
USA TODAY· 9 hours agoMedicare's Part D prescription drug coverage nearly $3 billion each year. The costs have increased...
3.6 million Medicare enrollees may now be eligible for Wegovy coverage
CNN via Yahoo News· 2 days agoAbout 3.6 million Medicare enrollees may qualify for coverage for the anti-obesity drug Wegovy,...
...Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to...
Sierra Sun Times· 7 hours agoIn a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of...
Millions of Medicare recipients could gain access to weight-loss drug
Newsweek· 1 day agoMillions of overweight or obese patients with heart conditions insured under Medicare could gain...
Why doesn't Medicare cover drugs like Ozempic for weight loss? - Marketplace
Marketplace· 1 week agoMedicare Part D, which provides prescription drug coverage, will now cover the weight-loss...
New rules mean 3.6 million Americans could get Wegovy via Medicare, costing billions
Medical Xpress· 1 day agoThe FDA's ruling potentially allows Wegovy prescription coverage for more than a quarter of 13.7...
Was President Biden correct in saying Medicare Part D will cap costs at $2,000 for drugs?
Gannett via AOL· 4 days agoThe vast majority of Medicare beneficiaries are enrolled in the program’s drug prescription benefit,...
FDA approval of Wegovy could give millions on Medicare access to weight-loss drug
PhillyVoice.com· 1 day agoWith this new approval, and the drug's possible dual use, millions of people on Medicare may be able...
Does Medicare pay for hearing aids?
CBS News· 2 hours agoThe average cost of hearing aids was around $4,600 as of 2018, but these days a pair of prescription-grade hearing aids can cost anywhere from $1,000 to...
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
Yahoo Finance· 2 hours agoThe company's mid-term pipeline strategy will be important, as some investors remain concerned...